Advertisement
Canada markets open in 7 hours 32 minutes

  • S&P/TSX

    22,011.72
    +139.76 (+0.64%)
     

  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     

  • DOW

    38,503.69
    +263.71 (+0.69%)
     

  • CAD/USD

    0.7318
    -0.0002 (-0.03%)
     

  • CRUDE OIL

    83.50
    +0.14 (+0.17%)
     

  • Bitcoin CAD

    91,234.37
    +311.98 (+0.34%)
     

  • CMC Crypto 200

    1,438.11
    +23.35 (+1.65%)
     

  • GOLD FUTURES

    2,341.50
    -0.60 (-0.03%)
     

  • RUSSELL 2000

    2,002.64
    +35.17 (+1.79%)
     

  • 10-Yr Bond

    4.5980
    -0.0520 (-1.12%)
     

  • NASDAQ futures

    17,738.25
    +131.50 (+0.75%)
     

  • VOLATILITY

    15.69
    -1.25 (-7.38%)
     

  • FTSE

    8,044.81
    +20.94 (+0.26%)
     

  • NIKKEI 225

    38,385.04
    +832.88 (+2.22%)
     

  • CAD/EUR

    0.6837
    +0.0001 (+0.01%)
     

Company News For Sep 4, 2019

Zacks Equity Research

  • Conn's, Inc.’s CONN shares rose 18.3% after the company reported second quarter fiscal 2020 earnings per share of $0.62, surpassing the Zacks Consensus Estimate of $0.51

  • The Medicines Company’s MDCO shares gained 10.4% after the company reported positive results from its ORION-11 trial at ESC Congress 2019.

  • Shares of Emergent BioSolutions Inc. EBS surged 14.5% after the company received a 10-year HHS contract to provide ACAM2000 smallpox vaccines to the U.S. Strategic National Stockpile

  • Shares of Royal Caribbean Cruises Ltd. RCL fell 1.4% afterthe reorts surfaced that the company could suffer losses of up to $0.05 a share in the current quarter due to the impact of Hurricane Dorian


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Royal Caribbean Cruises Ltd. (RCL) : Free Stock Analysis Report
 
Emergent Biosolutions Inc. (EBS) : Free Stock Analysis Report
 
The Medicines Company (MDCO) : Free Stock Analysis Report
 
Conn's, Inc. (CONN) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research